OncoMatch/Clinical Trials/NCT05223803
TERPS Trial for de Novo Oligometastic Prostate Cancer
Is NCT05223803 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Systemic Therapy for prostate cancer.
Treatment: Systemic Therapy — This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiation therapy
Exception: to an overlapping site of a target lesion that would preclude further radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- Maryland Proton Treatment Center · Baltimore, Maryland
- UMMC · Baltimore, Maryland
- Upper Chesapeake Health · Bel Air, Maryland
- Central Maryland Radiation Oncology · Columbia, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05223803 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages